Quick Facts
CagriSema is a highly anticipated, next-generation investigational weight-loss therapy thatcombines two powerful mechanisms of action into a single, once-weekly injection. Developed byNovo Nordisk, it co-formulates the well-established GLP-1 receptor agonist semaglutide withcagrilintide, a novel, long-acting amylin analogue. This dual-hormone approach is designed toproduce profound, synergistic effects on appetite regulation, gastric emptying, and metabolicoptimization, targeting weight loss outcomes that push the boundaries of pharmacologicalintervention.
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational peptide that belongs to a class of compounds known as triple receptor agonists. It is designed to activate three key metabolic hormone receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.Retatrutide is being studied in metabolic and obesity-related research because of its unique multi-receptor mechanism of action. Unlike traditional single-pathway compounds, Retatrutide targets multiple metabolic signaling pathways that researchers believe may influence appetite regulation, energy expenditure, glucose metabolism, and body weight.Developed by Eli Lilly and Company, Retatrutide has become one of the most widely discussed investigational peptides in metabolic research and is currently being evaluated in ongoing clinical studies. Retatrutide is a novel triple agonist peptide targeting the GLP-1, GIP, and glucagon receptors simultaneously.
Retatrutide (LY3437943) is a novel investigational peptide developed by Eli Lilly and Company. It is classified as a triple agonist, meaning it simultaneously activates three distinct hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-receptor engagement sets Retatrutide apart from every other metabolic research peptide currently in development or on the market.
As of 2023, Retatrutide has demonstrated unprecedented weight loss outcomes in Phase 2 clinical trials, with participants achieving a mean body weight reduction of up to 24.2% over 48 weeks — making it the most effective weight loss compound ever tested in a randomized controlled trial at the time of publication.
How Does Retatrutide Work?
Retatrutide works by binding to and activating three key metabolic hormone receptors in the body. Each receptor plays a distinct role in energy metabolism, appetite regulation, and glucose homeostasis. By engaging all three simultaneously, Retatrutide creates a synergistic effect that exceeds what any single or dual agonist can achieve.
Why Was Retatrutide Developed?
Retatrutide was developed to address the limitations of first and second generation metabolic peptides. While semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP) demonstrated significant efficacy, researchers hypothesized that adding glucagon receptor activity could further enhance energy expenditure through thermogenesis and hepatic fat reduction.
What Receptors Does It Target?
- GLP-1 Receptor — Controls insulin secretion, slows gastric emptying, and signals satiety to the brain
- GIP Receptor — Enhances insulin sensitivity, augments GLP-1 effects, and modulates lipid metabolism
- Glucagon Receptor — Increases energy expenditure via thermogenesis and reduces hepatic fat accumulation
How Is Retatrutide Different From Other Peptides?
- Only peptide in development targeting GLP-1, GIP AND glucagon simultaneously
- Highest weight loss outcomes ever recorded in a randomized controlled trial (24.2%)
- Significant reduction in liver fat — addressing NAFLD and metabolic liver disease
- Improvements in cardiometabolic markers including blood pressure and lipid profiles
- Once-weekly subcutaneous injection with a favorable tolerability profile
GLP-1 Receptor
Stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and activates satiety pathways in the hypothalamus to reduce food intake.
GIP Receptor
Enhances glucose-stimulated insulin secretion, improves insulin sensitivity in peripheral tissues, augments GLP-1 activity, and modulates lipid metabolism and adipose tissue function.
Glucagon Receptor
Increases hepatic glucose production, stimulates thermogenesis and energy expenditure, promotes lipolysis, and directly reduces liver fat — a key differentiator from GLP-1/GIP dual agonists.
The simultaneous activation of all three receptors creates a synergistic metabolic effect that exceeds single-receptor targeting alone.
Cagrisema Research Studies
Published clinical and preclinical research on Cagrisema.
Cagrisama Phase 2 Clinical Trial Results
- A 32-week, randomized, double-blind trial evaluating CagriSema against semaglutide alone, cagrilintide alone, and placebo.
- Participants receiving CagriSema achieved an average weight loss of 15.6%.
- This significantly outperformed the semaglutide monotherapy group (5.1% weight loss) and the cagrilintide monotherapy group (8.1% weight loss).
- The synergistic effect of the co-formulation clearly demonstrated superior efficacy over either component used in isolation.
Cagrisama Glycemic Control Outcomes
- In participants with Type 2 Diabetes, CagriSema produced a remarkable reduction in HbA1c levels, averaging a decrease of 2.18 percentage points.
- This reduction was significantly greater than the improvements seen with semaglutide alone, highlighting the powerful metabolic benefits of the dual-hormone approach.
Cagrisama Cardiometabolic Benefits
Early clinical data indicates rapid improvements in:
- Significant reductions in waist circumference and visceral adiposity.
- Normalization of fasting blood sugar and HbA1c.
- Improvements in systolic and diastolic blood pressure.
- Substantial improvements in lipid panels, notably drastic reductions in triglycerides.
Retatrutide vs Other Peptides
How does Retatrutide compare to other leading research peptides?
| Feature | Semaglutide | Tirzepatide | Liraglutide |
|---|---|---|---|
| Weekly Injection | Yes | Yes | Daily |
| Appetite Control | Excellent | Excellent | Moderate |
| Average Weight Loss | 15-17% | 20%+ | 6-8% |
| Dosing Frequency | Weekly | Weekly | Daily |
| Blood Sugar Support | Yes | Yes | Yes |
| Long-Term Data | Extensive | Growing | Established |
| Convenience | High | High | Moderate |
Tirzepatide vs Semaglutide
- Tirzepatide may produce greater weight loss due to its dual-agonist mechanism (GIP + GLP-1).
- Semaglutide currently has longer-term weight management data available.
- Both medications require physician supervision and dose titration.
Tirzepatide vs Liraglutide
- Tirzepatide requires only weekly injections, whereas Liraglutide requires daily administration.
- Tirzepatide produces vastly superior weight reduction (20%+ compared to Liraglutide's 6-8%).
Testing & Monitoring
Given its powerful metabolic impact, thorough evaluation is essential:
Medical History
MH- Personal or family history of Medullary Thyroid Carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis or severe gastrointestinal disease (like gastroparesis)
Laboratory Testing
LT<> <>Comprehensive Metabolic Panel (CMP)> <> Detailed liver function tests> <>Blood glucose and HbA1c> <>Fasting Lipid profile > >
Monitoring During Treatment
MDT- Aggressive monitoring of weight trajectory and gastrointestinal tolerability during the dose-escalation phase.
- Regular assessment of blood glucose levels, particularly in diabetic patients, to prevent hypoglycemia as insulin sensitivity improves.
- Regular blood work to ensure liver and kidney function remain optimal during rapid weight loss.
Frequently Asked Questions
Everything you need to know about peptide testing, certification, and compliance.
CagriSema is currently in Phase 3 clinical trials (the REDEFINE program). If the trials are
successful and regulatory bodies approve, it could be available in the coming years.
In Phase 2 trials, participants lost an average of 15.6% of their body weight in just 32 weeks.
Researchers anticipate even greater total weight loss in the longer, 68-week Phase 3 trials.
Because it combines two drugs that slow digestion, gastrointestinal side effects (nausea,
vomiting) are very common. However, trial data suggests the severity is generally mild to
moderate and comparable to high-dose GLP-1 therapies when titrated properly.
CagriSema is administered as a single, once-weekly subcutaneous injection, just like Wegovyor Mounjaro.
Rapid weight loss can lead to some muscle loss. However, some early research suggestsamylin analogues might help preserve lean mass better than GLP-1s alone. Regardless,clinical protocols strongly emphasize combining the medication with a high-protein diet andresistance training.
Certified Vendor Requirements
To qualify as a PeptideValidation.com Certified Vendor, companies must meet our rigorous multi-step testing and documentation standards. Certification is not bought — it is earned through independent verification.
🏆 Apply for CertificationTo qualify, vendors must:
-
Submit Batch Testing
Vendors must submit product samples for independent third-party lab testing before listing.
-
Pass Purity Requirements
All products must meet minimum purity thresholds verified by HPLC analysis.
-
Verify Identity via LC-MS
Molecular identity of each compound confirmed through liquid chromatography-mass spectrometry.
-
Maintain Full Documentation
COAs, batch records, and testing documentation must be publicly available on the vendor profile.
-
Undergo Quarterly Re-Testing
Certification requires mandatory re-testing every quarter to maintain active certified status.
Looking for Certified Peptide Sources?
Access our directory of independently reviewed and tested vendors who meet our rigorous testing and validation standards.
PeptideValidation.com is an independent testing and certification platform. We do not sell peptides or receive commission from vendors.
Access Certified Vendor DirectoryRelated Peptides
Tirzepatide
GLP-1 + GIP dual receptor agonist. FDA approved for type 2 diabetes and obesity management.
Learn More → 🧬GLP-1 AgonistSemaglutide
Gold standard GLP-1 receptor agonist. Marketed as Ozempic and Wegovy globally.
Learn More → ⚡Amylin AnalogueCagrilintide
Long-acting amylin analogue in Phase 3 trials as a combination therapy with semaglutide.
Learn More → 🔥Dual AgonistSurvodutide
GLP-1 + Glucagon dual agonist by Boehringer Ingelheim currently in Phase 3 clinical trials.
Learn More → 🏋️Dual AgonistMazdutide
GLP-1 + Glucagon dual agonist showing strong metabolic and weight loss outcomes in trials.
Learn More → 🩺Healing PeptideBPC-157
Body Protection Compound. Researched for tissue repair, gut healing, and accelerated recovery.
Learn More → 💪Recovery PeptideTB-500
Thymosin Beta-4 fragment. Researched for muscle recovery, flexibility, and anti-inflammatory effects.
Learn More →